Changeflow GovPing Pharma & Drug Safety EPO Patent Application: Anti-c-Met Antibody Dru...
Routine Notice Added Final

EPO Patent Application: Anti-c-Met Antibody Drug Conjugates

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Published March 18th, 2026
Detected March 23rd, 2026
Email

Summary

The European Patent Office has published a patent application (EP4656248A3) filed by AbbVie Manufacturing Management Unlimited Company for anti-c-Met antibody drug conjugates. The application details compositions and methods for using these conjugates, which are relevant to cancer treatments.

What changed

The European Patent Office (EPO) has published patent application EP4656248A3, filed by AbbVie Manufacturing Management Unlimited Company. This application pertains to anti-c-Met antibody drug conjugates (ADCs), including their compositions and methods of use, which are relevant for therapeutic applications, particularly in oncology.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it signifies potential future intellectual property developments in the field of antibody drug conjugates and cancer therapeutics. Companies operating in the pharmaceutical and biotechnology sectors should be aware of this filing as it relates to their research and development landscape.

Source document (simplified)

← EPO Patent Bulletin

ANTI-C-MET ANTIBODY DRUG CONJUGATES

Search Report EP4656248A3 Kind: A3 Mar 18, 2026

Applicants

AbbVie Manufacturing Management Unlimited Company

Inventors

PHILLIPS, Andrew C, REILLY, Regina M., DOHERTY, George A., JI, Cheng, BRUNCKO, Milan, BOGHAERT, Erwin R., ANDERSON, Mark

Abstract

The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.

IPC Classifications

C07K 16/28 20060101AFI20260206BHEP A61K 47/68 20170101ALI20260206BHEP C07D 491/22 20060101ALI20260206BHEP C07D 317/44 20060101ALI20260206BHEP C07D 317/70 20060101ALI20260206BHEP A61P 35/00 20060101ALI20260206BHEP C07K 5/062 20060101ALI20260206BHEP C07K 5/09 20060101ALI20260206BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4656248A3

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Patent Filing
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Intellectual Property Drug Development

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.